Headlines about LHC Group (NASDAQ:LHCG) have been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. LHC Group earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave media headlines about the health services provider an impact score of 46.3312631970426 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
LHC Group (NASDAQ LHCG) opened at $65.02 on Tuesday. The firm has a market cap of $1,196.00, a PE ratio of 28.03, a P/E/G ratio of 1.75 and a beta of 0.70. The company has a quick ratio of 1.77, a current ratio of 1.77 and a debt-to-equity ratio of 0.24. LHC Group has a 12 month low of $44.13 and a 12 month high of $76.14.
LHC Group (NASDAQ:LHCG) last released its quarterly earnings data on Monday, November 6th. The health services provider reported $0.64 EPS for the quarter, beating the Zacks’ consensus estimate of $0.60 by $0.04. The company had revenue of $272.90 million during the quarter, compared to the consensus estimate of $265.35 million. LHC Group had a net margin of 4.09% and a return on equity of 9.52%. LHC Group’s quarterly revenue was up 18.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.54 EPS. equities analysts anticipate that LHC Group will post 2.4 earnings per share for the current fiscal year.
A number of research firms have weighed in on LHCG. Zacks Investment Research lowered LHC Group from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. BidaskClub downgraded LHC Group from a “sell” rating to a “strong sell” rating in a research report on Thursday, December 7th. Oppenheimer reissued a “buy” rating and issued a $85.00 target price on shares of LHC Group in a research report on Thursday, December 7th. ValuEngine lowered shares of LHC Group from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Finally, Robert W. Baird set a $71.00 price target on shares of LHC Group and gave the company a “hold” rating in a report on Tuesday, November 28th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the company’s stock. LHC Group currently has an average rating of “Buy” and an average target price of $77.10.
ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/23/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-lhc-group-lhcg-share-price.html.
LHC Group Company Profile
LHC Group, Inc is a holding company. The Company provides post-acute healthcare services to patients through its home nursing agencies, hospice agencies, community-based services agencies and long-term acute care hospitals (LTACHs). The Company operates through four segments: home health services, hospice services, community-based services and facility-based services.
Receive News & Ratings for LHC Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LHC Group and related companies with MarketBeat.com's FREE daily email newsletter.